Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

No definition available.

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The amount of consideration recognized during the period for the milestone or milestones.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Name:	us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

Additional payments on achievement of series of milestones.

No definition available.

Name:	vicl_AdditionalPaymentsOnAchievementOfSeriesOfMilestones
Namespace Prefix:	vicl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Aggregate additional milestone payments.

No definition available.

Name:	vicl_AggregateAdditionalMilestonePayments
Namespace Prefix:	vicl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

License fees paid.

No definition available.

Name:	vicl_LicenseFeesPaid
Namespace Prefix:	vicl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Number of Products To Be Developed

No definition available.

Name:	vicl_NumberOfLicensedProductsAgreedToBeDeveloped
Namespace Prefix:	vicl_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Cash portion of payment to acquire license rights to Astellas antifungal compound.

No definition available.

Name:	vicl_PaymentsToAcquireLicenseRight
Namespace Prefix:	vicl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Astellas is eligible to receive up to $100 million in aggregate milestone payments under the antifungal compound in-license agreement with Vical.

No definition available.

Name:	vicl_PotentialFutureMilestonePaymentsDueMaximum
Namespace Prefix:	vicl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Recognized revenue relating to research and development services and manufacturing services performed by the Company.

No definition available.

Name:	vicl_RecognizedRevenueRelatedToContractServices
Namespace Prefix:	vicl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Revenue related to drug product delivered.

No definition available.

Name:	vicl_RevenueRelatedToDrugProductDelivered
Namespace Prefix:	vicl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vicl_AstellasInLicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=vicl_IPPOXFoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=vicl_CityOfHopeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=vicl_CytRxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: